122 results match your criteria primary gctb


Malignant Transformation of Giant Cell Tumor of Bone 7 years After Initial Surgery: A Case Report and Literature Review.

JBJS Case Connect 2021 04 20;11(2). Epub 2021 Apr 20.

Department of Orthopaedic Surgery, Kyushu Rosai Hospital, Japan.

Case: A 64-year-old man with a history of giant cell tumor of bone (GCTB) in the fibula 7 years earlier developed a recurrence with histologic features of osteosarcoma. Both the primary GCTB and the secondary osteosarcoma were found to have the H3F3A gene mutation. Despite immediate above-the-knee amputation, the patient died of respiratory failure because of lung metastases 3 months later. Read More

View Article and Full-Text PDF

The Clinical Characteristics and Prediction Nomograms for Primary Spine Malignancies.

Front Oncol 2021 26;11:608323. Epub 2021 Feb 26.

Department of Orthopedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Background: Primary spine malignancies (PSMs) are relatively rare in bone tumors. Due to their rarity, the clinical characteristics and prognostic factors are still ambiguous. In this study, we aim to identify the clinical features and proposed prediction nomograms for patients with PSMs. Read More

View Article and Full-Text PDF
February 2021

Primary Bone Tumors in North of Jordan.

J Epidemiol Glob Health 2021 03 11;11(1):132-136. Epub 2020 Nov 11.

Internship, King Abdullah University Hospital, Irbid 22110, Jordan.

Objective: Primary tumors of bone are relatively uncommon. Little information is available about the etiology, pathophysiology, risk factors and epidemiologic features of bone tumors. In this article, we present the epidemiological data about the primary (benign and malignant) bone tumors in Jordan. Read More

View Article and Full-Text PDF

Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.

BMC Cancer 2021 Jan 22;21(1):89. Epub 2021 Jan 22.

Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Bologna University, 40136, Bologna, Italy.

Background: Giant cell tumor of bone (GCTB) is a rare osteoclastogenic stromal tumor. GCTB can rarely undergo malignant transformation. This post hoc analysis evaluated and classified malignancies in patients with GCTB who received denosumab. Read More

View Article and Full-Text PDF
January 2021

Clinical and pathological analysis of giant cell tumor of bone with denosumab treatment and local recurrence.

J Orthop Sci 2020 Dec 23. Epub 2020 Dec 23.

Yokohama City University, Department of Orthopaedic Surgery, Yokohama, Japan.

Background: Giant cell tumor of bone (GCTB) is a primary bone tumor which comprises giant cells and two types of stromal cells. Recent studies have suggested therapeutic risks of denosumab. No previous studies have reported changes in serum TRACP-5b and SUVmax of F-FDG-PET/CT in recurred GCTB after denosumab treatment. Read More

View Article and Full-Text PDF
December 2020

The current standing on the use of denosumab in giant cell tumour of the bone.

J Orthop Surg (Hong Kong) 2020 Sep-Dec;28(3):2309499020979750

Tata Memorial Centre, Mumbai, Maharashtra, India.

Giant cell tumour of the bone (GCTB) has been classically treated surgically. With the advent of denosumab, there is potential to use it as a targeted therapy to downstage the tumour and control its progression. Like all new therapies, the dosage, duration, and long-term effects of treatment can only be determined over the time through numerous trials and errors. Read More

View Article and Full-Text PDF
December 2020

Malignancy in giant cell tumor of bone in the extremities.

J Bone Oncol 2021 Feb 5;26:100334. Epub 2020 Nov 5.

Deptartment of Orthopaedic Oncology Surgery, Beijing Jishuitan Hospital, Peking University, Beijing 100035, PR China.

Background: Malignancy in giant cell tumor of bone (GCTB) is a rare tumor with relevant literature being sparse. In primary malignant GCTB, distinct areas of benign GCTB are juxtaposed with high-grade sarcoma, while in secondary malignant GCTB sarcoma occurs at the site of previously managed GCTB. This study assesses the distinguishing characteristics of patients with this condition, the time interval for development of secondary malignant GCTB, the outcome of treatment, and explores factors associated with oncologic outcomes. Read More

View Article and Full-Text PDF
February 2021

Histone Mutations and Bone Cancers.

Adv Exp Med Biol 2021 ;1283:53-62

Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA.

Primary bone tumors are rare cancers that cause significant morbidity and mortality. The recent identification of recurrent mutations in histone genes H3F3A and H3F3B within specific bone cancers, namely, chondroblastomas and giant cell tumors of bone (GCTB), has provided insights into the cellular and molecular origins of these neoplasms and enhanced understanding of how histone variants control chromatin function. Somatic mutations in H3F3A and H3F3B produce oncohistones, H3. Read More

View Article and Full-Text PDF
January 2021

H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.

Histol Histopathol 2021 Jan 4;36(1):61-68. Epub 2020 Sep 4.

Department of Pathology, Beijing Jishuitan Hospital, The Fourth Medical College of Peking University, Beijing, China.

H3F3A mutations and the expression of glycine 34 to tryptophan (G34W) mutants in giant cell tumors of bone (GCTBs) and other bone tumors were detected to compare H3F3A mutation types and the expression of G34W-mutant protein in order to provide a theoretical basis for using H3F3A mutations as a diagnostic and differential-diagnostic tool for GCTBs. A total of 366 bone tumor cases were investigated. The cases involved 215 men and 151 women, whose median age was 29 years (3-84). Read More

View Article and Full-Text PDF
January 2021

Extended curettage versus en bloc resection for the treatment of grade 3 giant cell tumour of the knee with pathologic fracture: a retrospective study.

Int Orthop 2021 01 1;45(1):289-297. Epub 2020 Oct 1.

Bone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, Iran.

Purpose: For the treatment of giant cell tumour of the bone (GCTB) around the knee, preserving the native joint confers advantages over scarifying it. But, there is a controversy about the efficacy of intralesional curettage versus en bloc resection for treatment of such lesions. In this study, we compared local recurrence, functional outcomes, and complications of extended curettage and en bloc resection in these lesions. Read More

View Article and Full-Text PDF
January 2021

Secondary Osteoarthritis After Curettage and Calcium Phosphate Cementing for Giant-Cell Tumor of Bone Around the Knee Joint: Long-Term Follow-up.

JB JS Open Access 2020 Jul-Sep;5(3). Epub 2020 Aug 5.

Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.

Giant-cell tumor of bone (GCTB) is a locally aggressive intermediate bone tumor with a rarely metastasizing disposition. Standard surgical treatment consists of curettage, adjuvant treatment, and augmentation with allograft, autograft, or synthetics. Polymethylmethacrylate (PMMA) has been widely used for augmentation of the bone defect; however, the hyperthermic polymerization of PMMA may cause damage to articular cartilage, and the stiffness of the material may decrease the ability of the joint to absorb shock. Read More

View Article and Full-Text PDF

Drivers underpinning the malignant transformation of giant cell tumour of bone.

J Pathol 2020 12 6;252(4):433-440. Epub 2020 Oct 6.

Department of Pathology (research), University College London Cancer Institute, London, UK.

The rare benign giant cell tumour of bone (GCTB) is defined by an almost unique mutation in the H3.3 family of histone genes H3-3A or H3-3B; however, the same mutation is occasionally found in primary malignant bone tumours which share many features with the benign variant. Moreover, lung metastases can occur despite the absence of malignant histological features in either the primary or metastatic lesions. Read More

View Article and Full-Text PDF
December 2020

p62 overexpression promotes neoplastic stromal cell proliferation and is associated with the recurrence of giant cell tumor of bone.

Oncol Lett 2020 Oct 5;20(4):86. Epub 2020 Aug 5.

Department of Orthopaedics, Bone and Soft Tissue Tumors Research Center of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, Yunnan 650118, P.R. China.

Giant cell tumor of bone (GCTB) is an intermediate (locally aggressive) bone tumor with a recurrence rate of >30% following surgery. GCTB recurrence is ultimately due to the proliferation of neoplastic stromal (NS) cells. However, the precise mechanism underlying the regulation of NS cell proliferation remains unknown. Read More

View Article and Full-Text PDF
October 2020

The minimally invasive endoscopic technique for the treatment of symptomatic benign bone lesions: Preliminary results from a retrospective study.

J Bone Oncol 2020 Oct 2;24:100313. Epub 2020 Aug 2.

Department of Spine Surgery and Musculoskeletal Tumor, Zhongnan Hospital of Wuhan University, 168 Donghu Street, Wuchang District, Wuhan 430071, Hubei, People's Republic of China.

Objective: The present study aimed to evaluate the short-term clinical feasibility and efficacy of the minimally invasive endoscopic technique (MIET) for the treatment of symptomatic benign bone lesions.

Materials And Methods: This single-institution retrospective study investigated 34 patients with symptomatic benign bone lesions from December 2015 to June 2017. Patients involved in this study presented with definite indications for surgical intervention. Read More

View Article and Full-Text PDF
October 2020

Establishment and characterization of NCC-GCTB1-C1: a novel patient-derived cancer cell line of giant cell tumor of bone.

Hum Cell 2020 Oct 19;33(4):1321-1328. Epub 2020 Aug 19.

Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Giant cell tumor of bone (GCTB) is a rare osteolytic bone tumor, accounting for approximately 5% of all primary bone tumors. GCTB is characterized by unique giant cells. It is also characterized by recurrent mutations in the histone tail of the histone variant H3. Read More

View Article and Full-Text PDF
October 2020

Clinical, radiological and pathological outcomes following treatment of primary giant cell tumour of bone with Denosumab.

ANZ J Surg 2020 12 6;90(12):2553-2558. Epub 2020 Aug 6.

Department of Orthopaedics and The University of Melbourne Department of Surgery, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.

Background: Giant cell tumour of bone (GCTOB) is a relatively uncommon, benign, but locally aggressive neoplasm. Denosumab is a fully human monoclonal antibody with inhibitory effects on receptor activator of nuclear factor kappa-B ligand that has shown early promise as a possible treatment adjuvant for GCTB. However, much is still unknown about its current indications, long-term effects, the potential risk for rapid relapse and its involvement in sarcomatous transformation. Read More

View Article and Full-Text PDF
December 2020

Multiple primary tumors: a case report and review of the literature.

BMC Musculoskelet Disord 2020 Jun 22;21(1):394. Epub 2020 Jun 22.

Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, 100044, China.

Background: Multiple primary tumors, especially quadruple primary neoplasms is extremely rare. Fibrous dysplasia (FD), osteosarcoma (OS), and giant cell tumor of bone (GCTB) are three bone tumors with low incidence while primary pulmonary meningioma is a rare disease. In this case report, we present a unique synchronous occurrence of these four separate pathological conditions. Read More

View Article and Full-Text PDF

Current concepts in the treatment of giant cell tumour of bone.

Curr Opin Oncol 2020 07;32(4):332-338

Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands.

Purpose Of Review: Giant cell tumour of bone (GCTB) is an intermediate, locally aggressive primary bone tumour. In addition to local therapy, new drugs became available for this disease. Denosumab, a receptor activator of nuclear factor κ-B-ligand inhibitor, was introduced as systemic targeted therapy for advanced or inoperable and metastatic GCTB. Read More

View Article and Full-Text PDF

Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.

J Orthop Surg (Hong Kong) 2020 Jan-Apr;28(2):2309499020929786

Department of Human Pathology, Juntendo University School of Medicine, Tokyo, Japan.

Purpose: Giant cell tumor of bone (GCTB) is a local aggressive bone tumor, histologically classified as intermediate malignancy. Recently, the RANKL inhibitor, denosumab, was developed as a novel and effective treatment option for GCTB. Since the risk of preoperative use of denosumab with curettage had been previously reported, this study aimed to investigate the relationship between recurrences and clinicopathological features associated with adjuvant denosumab treatment in GCTB. Read More

View Article and Full-Text PDF
February 2021

Role of cancer stem cells in the development of giant cell tumor of bone.

Cancer Cell Int 2020 25;20:135. Epub 2020 Apr 25.

1Laboratory for Bone Metabolism, Key Laboratory for Space Bioscience and Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi'an, 710072 Shaanxi China.

The primary bone tumor is usually observed in adolescence age group which has been shown to be part of nearly 20% of the sarcomas known today. Giant cell tumor of bone (GCTB) can be benign as well as malignant tumor which exhibits localized dynamism and is usually associated with the end point of a long bone. Giant cell tumor (GCT) involves mononuclear stromal cells which proliferate at a high rate, multinucleated giant cells and stromal cells are equally present in this type of tumor. Read More

View Article and Full-Text PDF

[Expression of H3.3 G34W mutant-specific antibody in giant cell tumors of bone and its diagnostic value].

Zhonghua Bing Li Xue Za Zhi 2020 Feb;49(2):116-121

Department of Pathology, Medicine School of Nanjing University/Nanjing Jinling Hospital, Nanjing 210002, China.

To investigate the expression of H3.3 G34W mutant-specific antibody in giant cell tumors of bone (GCTB), and its value in the diagnosis of GCTB. Immunohistochemical (IHC) EnVision method was used to detect the expression of H3. Read More

View Article and Full-Text PDF
February 2020

Immunohistochemical analysis of 36 cases of chondroblastomas: A single institutional experience.

Ann Diagn Pathol 2020 Feb 13;44:151440. Epub 2019 Dec 13.

Department of Surgical Oncology (Bone and Soft Tissues, DMG), Tata Memorial Centre, HBNI University, Parel, Mumbai 400012, India.

Chondroblastoma is a relatively uncommon, primary benign bone tumor, frequently identified in young individuals. Despite its classical radiologic and histopathological features, at times, it is fraught with a diagnostic challenge, especially differentiating it from a giant cell tumor of bone (GCTB); an osteosarcoma and a chondrosarcoma. Lately, few studies have shown the diagnostic utility of immunohistochemical (IHC) expression DOG1 antibody in chondroblastomas. Read More

View Article and Full-Text PDF
February 2020

Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.

Med Mol Morphol 2020 Mar 20;53(1):1-6. Epub 2019 Nov 20.

Department of Anatomic Pathology, Graduate of School of Medical Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.

Giant cell tumor of bone (GCTB) is a locally aggressive bone tumor that frequently shows local recurrence and occasionally shows malignant transformation to high-grade sarcoma. Histologically, conventional GCTB is composed mainly of three types of cells: mononuclear neoplastic cells with an osteoblastic precursor phenotype, mononuclear histiocytic cells, and osteoclast-like multinucleated giant cells. These cells interact with each other via the RANKL-RANK axis and other mechanisms for tumor formation. Read More

View Article and Full-Text PDF

Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.

Lancet Oncol 2019 12 6;20(12):1719-1729. Epub 2019 Nov 6.

Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli/Department of Experimental, Diagnostic and Specialty Medicine, Università di Bologna, Bologna, Italy. Electronic address:

Background: Giant-cell tumour of bone (GCTB) is a rare, locally aggressive osteoclastogenic stromal tumour of the bone. This phase 2 study aimed to assess the safety and activity of denosumab in patients with surgically salvageable or unsalvageable GCTB.

Methods: In this multicentre, open-label, phase 2 study done at 30 sites in 12 countries we enrolled adults and skeletally mature adolescents (aged ≥12 years) weighing at least 45 kg with histologically confirmed and radiographically measurable GCTB, Karnofsky performance status 50% or higher (Eastern Cooperative Oncology Group status 0, 1, or 2), and measurable active disease within 1 year of study enrolment. Read More

View Article and Full-Text PDF
December 2019

Surgical Treatment Options for Giant Cell Tumors of Bone Around the Knee Joint: Extended Curettage or Segmental Resection?

Front Oncol 2019 24;9:946. Epub 2019 Sep 24.

Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.

This study aimed to compare and evaluate the oncological and functional prognosis of two surgical approaches for giant cell tumor of the bone (GCTB) around the knee joint and provide worthy suggestion for clinical treatment. This study included 93 patients, who were divided into the extended curettage (EC) group and segmental resection (SR) group. Relevant preoperative and postoperative data were collected, oncological and functional prognosis were evaluated, and postoperative complications of the two groups were analyzed. Read More

View Article and Full-Text PDF
September 2019

Evaluation of Local Recurrence in Giant-Cell Tumor of Bone Treated by Neoadjuvant Denosumab.

Clin Orthop Surg 2019 Sep 12;11(3):352-360. Epub 2019 Aug 12.

Department of Musculoskeletal Oncology, HCG Hospital, Bangalore, India.

Background: Giant-cell tumor of bone (GCTB) is a locally aggressive primary benign tumor presenting as an expansile osteolytic lesion affecting the epiphysis of long bones. Denosumab halts the osteolysis by giant cells thereby downstaging the tumor, helping in performing less morbid procedures to remove the tumor. Our aim was to report the incidence of local recurrence (LR) in patients operated following neoadjuvant denosumab, to investigate factors associated with LR following extended curettage for GCTB, and to compare the postoperative functional and oncological outcome of patients operated with and without neoadjuvant denosumab. Read More

View Article and Full-Text PDF
September 2019

Simvastatin Possesses Antitumor and Differentiation-Promoting Properties That Affect Stromal Cells in Giant Cell Tumor of Bone.

J Orthop Res 2020 02 11;38(2):297-310. Epub 2019 Sep 11.

Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Hong Kong.

Giant cell tumor of bone (GCTB) is a locally aggressive destructive bone lesion. The management of pulmonary metastasis and local recurrence after the surgical treatment of GCTB remains a challenge. Pathologically, stromal cells in GCTB are known as primary neoplastic cells and are recognized as incompletely differentiated preosteoblasts. Read More

View Article and Full-Text PDF
February 2020

Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial.

Oncologist 2019 07 30;24(7):889-e421. Epub 2019 Apr 30.

Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.

Lessons Learned: Adjuvant treatment with zoledronic acid did not decrease the recurrence rate of giant cell tumor of bone (GCTB) in this study. The efficacy could not be determined because of the small sample size.GCTB recurrences, even in the denosumab era, are still an issue; therefore, a randomized study exploring the efficacy of zoledronic acid in the adjuvant setting in GCTB is still valid. Read More

View Article and Full-Text PDF

Characterization of Three Novel H3F3A-mutated Giant Cell Tumor Cell Lines and Targeting of Their Wee1 Pathway.

Sci Rep 2019 04 23;9(1):6458. Epub 2019 Apr 23.

Institute of Pathology, Ulm University, Ulm, Germany.

The giant cell tumor of bone (GCTB) is a locally aggressive primary bone tumor that is composed of mononuclear stroma cells, scattered macrophages, and multinucleated osteoclast-like giant cells which cause pathologic osteolysis. The stroma cells represent the neoplastic population of the tumor and are characterized by the H3F3A mutation G34W. This point mutation is regarded as the driver mutation of GCTB. Read More

View Article and Full-Text PDF